Literature DB >> 28573688

Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: A systematic review, meta-analysis, and case series.

Rosemary Grain1, John Lally2,3,4,5, Brendon Stubbs6,7, Steffi Malik8, Anne LeMince3, Timothy R Nicholson2, Robin M Murray2,3, Fiona Gaughran2,3,9.   

Abstract

Antibodies to the voltage-gated potassium channel (VGKC) complex and glutamic acid decarboxylase (GAD) have been reported in some cases of psychosis. We conducted the first systematic review and meta-analysis to investigate their prevalence in people with psychosis and report a case series of VGKC-complex antibodies in refractory psychosis. Only five studies presenting prevalence rates of VGKC seropositivity in psychosis were identified, in addition to our case series, with an overall prevalence of 1.5% (25/1720) compared to 0.7% in healthy controls (12/1753). Meta-analysis established that the pooled prevalence of GAD65 autoantibodies was 5.8% (95% confidence interval [CI]: 2.0-15.6%; I2  = 91%; nine studies) in psychotic disorders, with a prevalence of 4.6% (95%CI: 1.2-15.9%; nine studies; I2  = 89%) and 6.2% (95%CI: 1.2-27.0%; two studies; I2  = 69%) in schizophrenia and bipolar disorder, respectively. People with psychosis were more likely to have GAD65 antibodies than controls (odds ratio [OR], 2.24; 95%CI: 1.28-3.92%; P = 0.005; eight studies; I2  = 0%). Among 21 participants with treatment-resistant psychosis, none had VGKC antibodies. The prevalence of VGKC antibodies is low in psychosis. Our preliminary meta-analysis suggests that GAD autoantibodies are more common in people with psychosis than in controls, although few studies accounted for the possibility of co-existing type 1 diabetes mellitus and the clinical significance of reported GAD titers remains unclear. The paucity of studies reporting thresholds for defining GAD abnormality and rates of comorbid type 1 diabetes mellitus precludes interpretations regarding the influence of GAD antibodies on the development of psychotic disorders and may have led to an overestimate of the prevalence of GAD. Our case series fails to support the hypothesis that VGKC antibodies are linked to treatment resistance in psychosis, but the literature to date is remarkably sparse.
© 2017 The Authors. Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology.

Entities:  

Keywords:  antibodies; encephalitis; glutamic acid decarboxylase; schizophrenia; voltage-gated potassium channel complex

Mesh:

Substances:

Year:  2017        PMID: 28573688     DOI: 10.1111/pcn.12543

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  7 in total

1.  The significance of anti-neuronal antibodies for acute psychiatric disorders: a retrospective case-controlled study.

Authors:  Morten B Schou; Sverre Georg Sæther; Ole Kristian Drange; Karoline Krane-Gartiser; Solveig K Reitan; Arne E Vaaler; Daniel Kondziella
Journal:  BMC Neurosci       Date:  2018-11-03       Impact factor: 3.288

2.  Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach.

Authors:  Niels Hansen; Michael Lipp; Jonathan Vogelgsang; Ruth Vukovich; Tristan Zindler; Daniel Luedecke; Stefan Gingele; Berend Malchow; Helge Frieling; Simone Kühn; Johannes Denk; Jürgen Gallinat; Thomas Skripuletz; Nicole Moschny; Jens Fiehler; Christian Riedel; Klaus Wiedemann; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi
Journal:  Brain Behav Immun Health       Date:  2020-10-01

Review 3.  Catatonic Schizophrenia Associated With Cerebrospinal GAD65 Autoantibodies: Case Report and Literature Review.

Authors:  Niels Hansen; Claudia Bartels; Bianca Teegen; Jens Wiltfang; Berend Malchow
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

4.  Psychotic Symptoms as the Initial Presentation of a Long-Lasting Misdiagnosed Anti-GAD65 Autoimmune Encephalitis: An Emblematic Case and Literature Review.

Authors:  Jianjun Wang; Shenglan Gong; Fanxin Kong; Dongbin Cai; Binqing Huang; Haotao Zheng; Songjun Lin; Jinfang Li; Tianfeng Zhang
Journal:  Front Psychiatry       Date:  2022-02-23       Impact factor: 4.157

5.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

6.  A prospective three-year follow-up study on the clinical significance of anti-neuronal antibodies in acute psychiatric disorders.

Authors:  M B Schou; S G Sæther; O K Drange; E Brenner; J Crespi; L Eikenes; M S Mykland; C Pintzka; A K Håberg; T Sand; A Vaaler; D Kondziella
Journal:  Sci Rep       Date:  2019-12-31       Impact factor: 4.379

7.  Diagnosing Organic Causes of Schizophrenia Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in Psychosis (FDPP).

Authors:  Dominique Endres; Miriam Matysik; Bernd Feige; Nils Venhoff; Tina Schweizer; Maike Michel; Sophie Meixensberger; Kimon Runge; Simon J Maier; Kathrin Nickel; Karl Bechter; Horst Urbach; Katharina Domschke; Ludger Tebartz van Elst
Journal:  Diagnostics (Basel)       Date:  2020-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.